Alirocumab efficiently reduces LP(A) levels by lowering Apolipoprotein (A) [APO(A)] production rate in Non-Human primates (NHP)

Authors :: Bruno Poirier
Rose-Hélène Blanchard
Thi-Thu-Trang Tran
Etienne Guillot
Jean-Chistophe Le Bail
Mikaël Croyal
Michel Krempf
Christophe Boixel
Gilles Lambert
Aurélie Thedrez
Elise F. Villard
Physiopathologie des Adaptations Nutritionnelles (PhAN)
Université de Nantes (UN)-Institut National de la Recherche Agronomique (INRA)
Sanofi
Université de La Réunion (UR)
European Atherosclerosis Society. SWE.
Source :: Atherosclerosis, 85th Congress of the European-Atherosclerosis-Society (EAS), 85th Congress of the European-Atherosclerosis-Society (EAS), European Atherosclerosis Society. SWE., Apr 2017, Prague, Czech Republic. pp.1
Publication Year :: 2017
Publisher :: HAL CCSD, 2017.
Abstract: International audience

Subjects :: medicine.medical_specialty
Endocrinology
Biochemistry
Apolipoprotein B
biology
Internal medicine
[SDV]Life Sciences [q-bio]
medicine
biology.protein
Cardiology and Cardiovascular Medicine
ComputingMilieux_MISCELLANEOUS
Production rate
Alirocumab

Language :: English
Database :: OpenAIRE
Journal :: Atherosclerosis, 85th Congress of the European-Atherosclerosis-Society (EAS), 85th Congress of the European-Atherosclerosis-Society (EAS), European Atherosclerosis Society. SWE., Apr 2017, Prague, Czech Republic. pp.1
Accession number :: edsair.doi.dedup.....006af85719aef9f836bb623838cc5f44

Tools